1474-1776

View prefix report (10.1038)

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 24 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact24 DOIs
2

Attach ORCID iDs across 24 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact24 DOIs
3

Deposit reference lists for 10 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Medium impact10 DOIs

DOIs for this ISSN

Showing the top 5 of 24 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 FDA approves first all-oral sleeping sickness drug (10.1038/d41573-021-00140-5)
Abstract References ORCID
67.73 7
2 John P. A. Ioannidis (10.1038/nrd4317)
Abstract References ORCID
22.58 1
3 The evolving paradigm of cancer trials (10.1038/nrd.2017.210)
Abstract ORCID
15.05 1
4 Rebalancing protein synthesis in fragile X syndrome (10.1038/d41573-020-00100-5)
Abstract ORCID
0.00 0
5 The importance of persistence in cancer drug development (10.1038/d41573-021-00192-7)
Abstract References ORCID
0.00 0
6 Pfizer buys Biohaven’s migraine drugs for $11.6 billion (10.1038/d41573-022-00093-3)
Abstract References ORCID
0.00 0
7 Vaccine exposes tumours to immune cell attack (10.1038/d41573-022-00105-2)
Abstract ORCID
0.00 0
8 The improving benefit–risk balance of phase I cancer trials (10.1038/d41573-022-00144-9)
Abstract References ORCID
0.00 0
9 A new path to targeted protein degradation? (10.1038/d41573-022-00147-6)
Abstract References ORCID
0.00 0
10 Neutralizing Zika virus (10.1038/d41573-022-00201-3)
Abstract ORCID
0.00 0
11 A specific biomarker for insoluble tau (10.1038/d41573-023-00126-5)
Abstract ORCID
0.00 0
12 Targeting tumour-associated bacteria (10.1038/d41573-023-00176-9)
Abstract ORCID
0.00 0
13 AI serves up target and inhibitor for lung fibrosis (10.1038/d41573-024-00053-z)
Abstract ORCID
0.00 0
14 Fine print TRIPS up multinational and Indian companies (10.1038/nrd1650)
Abstract ORCID
0.00 0
15 Oncology (10.1038/nrd1737)
Abstract References ORCID License
0.00 0
16 News In Brief (10.1038/nrd1945)
Abstract ORCID
0.00 0
17 German firms resort to consolidation to restore glory days (10.1038/nrd2048)
Abstract References ORCID
0.00 0
18 Striking the right balance (10.1038/nrd2178)
Abstract ORCID
0.00 0
19 Getting to the root of relapse (10.1038/nrd2214)
Abstract ORCID
0.00 0
20 Dealing with a data deficit (10.1038/nrd2440)
Abstract ORCID
0.00 0
21 In this issue (10.1038/nrd2484)
Abstract References ORCID
0.00 0
22 Blocking brain enzyme curbs appetite (10.1038/nrd2621)
Abstract ORCID
0.00 0
23 In this issue (10.1038/nrd2870)
Abstract References ORCID
0.00 0
24 News in brief (10.1038/nrd3108)
Abstract ORCID
0.00 0